Yale Catriona (CIK 1779308) reported 39 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2025-12-09). Recent activity: Sell AKRO (27,227 shares), Sell AKRO (47,573 shares), Buy AKRO (3,527 shares), Buy AKRO (4,739 shares), Sell AKRO (659 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-09 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 27,227 | $0 |
| 2025-12-09 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 47,573 | $0 |
| 2025-11-06 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Buy | 3,527 | $99,990 |
| 2025-11-06 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Buy | 4,739 | $99,993 |
| 2025-09-12 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 659 | $28,350 |
| 2025-07-18 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Buy | 10,000 | $198,700 |
| 2025-07-18 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 8,658 | $457,748 |
| 2025-07-18 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 1,342 | $71,757 |
| 2025-07-02 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Buy | 890 | $21,244 |
| 2025-06-20 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 2,895 | $158,646 |
| 2025-06-20 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Buy | 10,000 | $211,000 |
| 2025-06-20 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 6,210 | $333,974 |
| 2025-06-20 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 1,633 | $89,554 |
| 2025-06-20 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 895 | $49,690 |
| 2025-06-12 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 2,803 | $151,362 |
| 2025-05-19 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Buy | 10,000 | $211,000 |
| 2025-05-19 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 2,837 | $108,373 |
| 2025-05-19 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 2,779 | $109,659 |
| 2025-05-19 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 4,384 | $174,965 |
| 2025-04-16 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Buy | 9,073 | $191,440 |
| 2025-04-16 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 7,873 | $297,599 |
| 2025-04-16 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 1,200 | $46,344 |
| 2025-03-18 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Buy | 10,000 | $211,000 |
| 2025-03-18 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 8,201 | $366,585 |
| 2025-03-18 | Akero Therapeutics, Inc. (AKRO) | Chief Development Officer | Sell | 1,799 | $81,045 |
Source: SEC Form 4 filings · as of 2025-12-09